



Trimurthi Drugs & Pharmaceuticals Ltd.

Date: 12-02-2016

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai. - 400 001

The Manager (Listing
Department)
The Ahmedabad Stock
Exchange Ltd.,
Kamadhenu Complex,
Opp. Sahajanand College,
Panjarapole,
Ahmedabad

To,
The Manager (Listing
Department)
The Madras Stock
exchange,
Chennai

Sub : Outcome of the Board meeting.

The meeting of the Board of Directors of the company was held at 04:30 pm today. The out come of the meeting is under:


The Board has considered and approved the minutes of the previous board meeting.


The Board has considered and approved the Standalone and Consolidated Un-audited financials for the Quarter ended 31st December, 2015.

The Board has considered and approved postal ballot for change of Name and objects of the Company and in the process has appointed scrutinizer and finalized the calendar of events for postal ballot.

There being no other matter the meeting was concluded at around 05:30 pm with vote of thanks.

Thanking you
Yours truly,
for TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED.


Arun Kumar Bhangadia
Managing Director
DIN: 00021024





Trimurthi Drugs & Pharmaceuticals Ltd.

Date : 12.02.2016

To,

The Secretary,
B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai. - 400 001

The Manager (Listing
Department)
The Ahmedabad Stock
Exchange Ltd.,
Kamadhenu Complex,
Opp. Sahajanand College,
Panjarapole,
Ahmedabad

To,
The Manager (Listing
Department)
The Madras Stock
exchange,
Chennai

Dear Sir,

Sub: Results for Quarter and Nine Months ended 31-12-2015

Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing obligations and Disclosures Requirements) Regulations, 2015 the board of Directors of the company as its meeting held on Friday, the 12th Day of February, 2016 have approved and taken on record, inter alia the unaudited financial Results of the company for the quarter ended 31st December, 2015.


A copy of the results along with limited Review Report of the auditors of the company, as required under Regulation 33 of the Listing Regulations, is enclosed herewith.

Kindly acknowledge the receipt of the same.

Thanking you

for **TRIMURTHI DRUGS & PHARMACEUTICALS LTD**


Arun Kumar Bhangadia
Managing Director
DIN: 00021024






Trimurthi Drugs & Pharmaceuticals Ltd.

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2015

PART-I						
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR QUARTER III AND THREE MONTHS ENDED 31/12/2015						
Particulars	3 Months ended 31-12-2015	Preceding 3 months ended 30-09-2015	Corresponding 3 months ended 31-12-2014	Year to date figures for the current period ended 31-12-2015	Year to date figures for the previous period ended 31-12-2014	Year ended 31-03-2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income From Operations						
Net Sales / Income from Operations	121.18	120.73	128.65	367.05	411.17	511.51
Other Operating Income	27.45	22.64	29.05	73.85	83.47	123.45
Total Operating Income(Net)	148.63	143.37	157.70	440.90	494.64	634.96
2. Expenditure						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	Nil
b. Purchase of Traded Goods	102.56	115.36	131.24	327.23	376.60	472.24
c. (Increase)/Decrease in stock in trade and work in Progress	4.67	(10.03)	(20.40)	(4.50)	(17.12)	(12.80)
d. Employees Cost	13.44	12.71	8.29	37.61	18.68	35.86
e. Depreciation	10.51	6.98	8.15	26.30	23.52	40.89
f. Other Expenditure	5.95	9.74	8.52	25.34	23.85	50.63
Total	137.13	134.77	135.81	411.98	425.54	586.82
3. Profit/ (Loss) from Operations before Other Income, Finance Cost & Exceptional Items (2-1)	11.49	8.60	21.89	28.92	69.11	48.14
4. Other Income	2.79	3.90		11.25	0.00	(20.63)
5. Profit/ (Loss) from Ordinary Activities before Finance Cost & Exceptional Items (3+4)	14.28	12.50	21.89	40.17	69.11	27.51
6. Finance Cost	0.00	0.00	0.11	0.00	0.26	0.39
7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)	14.28	12.50	21.78	40.17	68.85	27.12
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
9. Profit/ (Loss) from Ordinary activities before tax (7+8)	14.28	12.50	21.78	40.17	68.85	27.12
10. Tax Expense (Including Deferred Tax)	2.52	4.31	7.27	10.44	21.67	12.94
11. Net Profit/ (Loss) from Ordinary activities after Tax (9+10)	11.76	8.20	14.51	29.73	47.18	14.18
12. Extraordinary Items(Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil	Nil
13. Net Profit/ (Loss) for the period (11+12)	11.76	8.20	14.51	29.73	47.18	14.18
14. Share Of Profit/(loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
15. Minority Interest	1.52	1.66	1.28	4.96	7.93	5.67
16. Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)	10.24	6.54	13.23	24.78	39.25	8.51
17. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00	810.00
18. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	332.90	332.90	334.84	332.90	334.84	336.82
19. Earnings Per Share (EPS)						
i. Basic & Diluted before extraordinary items (not annualised)	0.13	0.08	0.16	0.31	0.48	0.11
ii. Basic & Diluted after extraordinary items (not annualised)	0.13	0.08	0.16	0.31	0.48	0.11





Trimurthi Drugs & Pharmaceuticals Ltd.

Segment Reporting

Particulars	Quarters ended			Period ended		Year ended
	31/12/2015 Unaudited	30/09/2015 Unaudited	31/12/2014 Unaudited	31/12/2015 Unaudited	31/12/2014 Unaudited	31/03/2015 Audited
1. Segment Revenue						
a. Pharma Business	121.62	122.68	128.65	371.62	411.17	520.68
b. Financial Services	27.01	20.69	29.05	69.28	83.47	114.28
c. Investments	2.79	3.90	0.00	11.25	0.00	(19.67)
d. Foods	0.00	0.00	0.00	0.00	0.00	0.00
e. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
Total	151.42	147.27	157.70	452.15	494.64	615.29
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Net Sales/ Income From Operations	151.42	147.27	157.70	452.15	494.64	615.29
2. Segment Profits (Before tax & Interest From Each Segment)						
a. Pharma Business	3.16	7.34	7.65	16.49	27.52	16.82
b. Financial Services	7.82	1.93	14.13	13.00	41.33	31.00
c. Investments	3.29	3.22	0.00	10.68	0.00	(20.70)
d. Foods	0.00	0.00	0.00	0.00	0.00	0.00
e. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
Total	14.28	12.50	21.78	40.16	68.85	27.12
Less:						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Total Profit Before Tax	14.28	12.50	21.78	40.16	68.85	27.12
3. Capital Employed						
a. Pharma Business	57.05	85.66	127.52	57.05	127.52	68.68
b. Financial Services	977.66	1039.60	1026.58	977.66	1026.58	940.43
c. Investments	108.24	75.58	5.00	108.24	5.00	113.79
d. Foods	64.33	0.00	0.00	64.33	0.00	0.00
e. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
Total	1207.28	1200.85	1159.09	1207.28	1159.09	1122.90

Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on **12-02-2016**.
- The financial results for the quarter ended 31-12-2015 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- The above results includes the results of M/s Trimurthi Foods Limited which has become the subsidiary of the Company during the quarter.

Place : Hyderabad,
Date : 12-02-2016



Trimurthi Drugs & Pharmaceuticals Ltd.


TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2015

PART-II

Select Information for Quarter II and Three months Ended 31/12/2015

Particulars	3 Months ended 31-12-2015	Preceding 3 months ended 30-09-2015	Corresponding 3 months ended 31-12-2014	Year to date figures for the current period ended 31-12-2015	Year to date figures for the current period ended 31-12-2014	Year ended 31-03-2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A. Particulars Of Share Holding						
1. Public Share Holding						
- Number of Shares	2849600	2849600	3102200	2849600	3102200	2849600
- Percentage of shareholding	35.18%	35.18%	38.30%	35.18%	38.30%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5250400	5250400	4997800	5250400	4997800	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	64.82%	61.70%	64.82%	61.70%	64.82%
Particulars	9 Months Ended (31/12/2015)					
B. Investor Complaints						
Pending at the beginning of the quarter				-NIL-		
Received during the quarter				-NIL-		
Disposed during the quarter				-NIL-		
Remaining unsolved during the quarter				-NIL-		





Trimurthi Drugs & Pharmaceuticals Ltd.
STANDALONE UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2015

PART-I

(Rs. In Lakhs)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR QUARTER II AND THREE MONTHS ENDED 31-12-2015

Particulars	3 Months ended 31-12-2015	Preceeding 3 months ended 30-09-2015	Corresponding 3 months ended 31-12-2014	Year to date figures for the current period ended 31-12-2015	Year to date figures for the previous year ended 31-12-2014	Year ended 31-03-2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income From Operations						
Net Sales / Income from Operations	0.00	0.00	(0.00)	0.00	31.40	31.40
Other Operating Income	24.08	20.65	30.83	65.79	83.47	114.20
Total Operating Income(Net)	24.08	20.65	30.83	65.79	114.87	145.60
2. Expenditure						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	
b. Purchase of Traded Goods/Shares	0.00	0.00	0.00	0.00	0.08	0.00
c. (Increase)/Decrease in stock in trade and work in Progress	0.00	0.00	0.00	0.00	32.21	32.21
d. Employees Cost	5.76	5.67	1.42	15.57	3.85	6.20
e. Rent	0.60	0.30	0.34	1.10	0.84	
f. Depreciation	10.97	6.12	7.21	25.54	22.54	39.50
g. Other Expenditure	3.18	4.38	4.91	13.53	14.24	37.70
Total	20.51	16.47	13.87	55.74	73.76	115.83
Profit/ (Loss) from Operations before Other Income, Finance Cost & Exceptional Items (2-1)	3.57	4.18	16.96	10.05	41.10	29.80
3. Other Income	2.76	3.79	0.00	11.12	0.00	(20.60)
Profit/ (Loss) from Ordinary Activities before Finance Cost & Exceptional Items (3+4)	6.33	7.97	16.96	21.17	41.10	9.17
6. Finance Cost	0.00	0.00	0.11	0.00	0.26	0.30
7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)	6.33	7.97	16.85	21.17	40.84	8.78
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
9. Profit/ (Loss) from Ordinary activities before tax (7+8)	6.33	7.97	16.85	21.17	40.84	8.78
10. Tax Expense (Including Deferred Tax)	1.55	2.12	5.21	5.34	13.00	6.90
11. Net Profit/ (Loss) from Ordinary activities after Tax (9+10)	4.78	5.86	11.64	15.83	27.85	1.86
12. Extraordinary Items(Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil	Nil
13. Net Profit/ (Loss) for the period (11+12)	4.78	5.86	11.64	15.83	27.85	1.86
14. Share Of Profit/(loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
15. Minority Interest	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)	4.78	5.86	11.64	15.83	27.85	1.86
17. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00	810.00
18. Reserves excluding revaluation reserves, as per balance sheet of previous accounting year	324.27	324.27	334.84	324.27	334.84	334.84
19. Earnings Per Share (EPS)						
i. Basic & Diluted before extraordinary items (not annualised)	0.06	0.07	0.14	0.20	0.34	0.02
ii. Basic & Diluted after extraordinary items (not annualised)	0.06	0.07	0.14	0.20	0.34	0.02



Segment Reporting

Trimurthi Drugs & Pharmaceuticals Ltd.

Particulars	Quarters ended			Period ended		Year ended
	31/12/2015 Unaudited	30/09/2015 Unaudited	31/12/2014 Unaudited	31/12/2015 Unaudited	31/12/2014 Unaudited	31/03/2016 Audited
1. Segment Revenue						
a. Pharma Business	0.00	0.00	0.00	0.00	31.40	31.40
b. Financial Services	24.08	20.65	30.83	65.79	83.47	114.27
c. Investments	2.76	3.79	0.00	11.12	0.00	(19.6)
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
Total	26.84	24.44	30.83	76.91	114.87	125.9
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-N
Net Sales/ Income From Operations	26.84	24.44	30.83	76.91	114.87	125.9
2. Segment Profits (Before tax & Interest From Each Segment)						
a. Pharma Business	0.00	0.00	0.00	0.00	(1.47)	(1.4)
b. Financial Services	3.06	4.85	16.85	10.63	42.31	30.8
c. Investments	3.26	3.12	0.00	10.54	0.00	(20.5)
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
Total	6.32	7.97	16.85	21.17	40.84	8.7
Less:						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-N
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-N
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-N
Total Profit Before Tax	6.32	7.97	16.85	21.17	40.84	8.7
3. Capital Employed						
a. Pharma Business	9.18	13.82	16.66	9.18	16.66	11.8
b. Financial Services	962.94	914.13	1099.53	962.94	1099.53	962.1
c. Investments	172.98	207.38	31.50	172.98	31.50	140.2
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
Total	1145.10	1135.33	1147.69	1145.10	1147.69	1114.2

Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on **12-02-2016**.
- The financial results for the quarter ended 31-12-2015 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.

Place : Hyderabad,
Date : 12-02-2016





Trimurthi Drugs & Pharmaceuticals Ltd.
STANDALONE UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2015

PART-II

SELECT INFORMATION FOR QUARTER III AND THREE MONTHS ENDED 31-12-2015

Particulars	3 Months ended 31-12-2015	Preceding 3 months ended 30-09-2015	Corresponding 3 months ended 31-12-2014	Year to date figures for the current period ended 31-12-2015	Year to date figures for the previous period ended 31-12-2014	Year ended 31-03-2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A. Particulars Of Share Holding						
1. Public Share Holding						
- Number of Shares	2849600	2849600	3366200	2849600	3366200	2849600
- Percentage of shareholding	35.18%	35.18%	41.56%	35.18%	41.56%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5250400	5250400	4733800	5250400	4733800	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	64.82%	58.44%	64.82%	58.44%	64.82%
Particulars	3 Months Ended (31/12/2015)					
B. Investor Complaints						
Pending at the beginning of the quarter	-NIL-					
Received during the quarter	-NIL-					
Disposed during the quarter	-NIL-					
Remaining unsolved during the quarter	-NIL-					





K. Venkateswara Rao & Associates

Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.
e-mail: v_kommineni@yahoo.com

Annexure V to Clause 41

Review Report to:
To
The Board of Directors,
Trimurthi Drugs & Pharmaceuticals Limited
Hyderabad.

Limited Review Report for the Quarter ended 31st December, 2015

We have reviewed the accompanying statement of unaudited financial results of M/s **TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED** for the period ended **31st December, 2015**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement(SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquires of company personnel and analytical procedures applied to financial data and this provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards (Note 1) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing Obligations and Disclosures Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

PLACE : HYDERABAD
DATE : 12.02.2016

K.VENKATESWARA RAO & ASSOCIATES
CHARTERED ACCOUNTANTS
FRN: 006374S

K.VENKATESWARA RAO
PROPRIETOR
M.No. 27305

